Figure 1.

Recommendations for the prophylactic management of skin reactions induced by EGFR inhibitors: general basic skin care recommendations for the early phase (A) and specific prophylaxis recommendations for acne-like rash (B), starting with the first cetuximab dose. Level of evidence and grades of recommendations reflect the following scoring system: Levels of evidence are as follows: IA, evidence from meta-analysis of randomized controlled trials; IB, evidence from at least one randomized controlled trial; IIA, evidence from at least one controlled study without randomization; IIB, evidence from at least one other type of quasi-experimental study; III, evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; and IV, evidence from expert committee reports or opinions or clinical experience of respected authorities, or both. Grades of recommendation are as follows: A, directly based on level I evidence; B, directly based on level II evidence or extrapolated recommendations from level I evidence; C, directly based on level III evidence or extrapolated recommendations from level I or II evidence; and D, directly based on level IV evidence or extrapolated recommendations from level I, II, or III evidence.

Abbreviations: DAC, Deutscher Arzneimittel-Codex; LOE, level of evidence.